These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 15757437

  • 1. Alemtuzumab.
    Ravandi F, O'Brien S.
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [Abstract] [Full Text] [Related]

  • 2. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F, O'brien S.
    Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
    [Abstract] [Full Text] [Related]

  • 3. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
    Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, Watanabe T, Asai T, Izutsu K, Ogawa S, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2006 Nov; 81(11):875-9. PubMed ID: 16862551
    [Abstract] [Full Text] [Related]

  • 5. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
    Boyd K, Dearden CE.
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
    [Abstract] [Full Text] [Related]

  • 6. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE, Matutes E.
    Best Pract Res Clin Haematol; 2006 Apr; 19(4):795-810. PubMed ID: 16997184
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T.
    BioDrugs; 2005 May 28; 19(1):9-22. PubMed ID: 15691213
    [Abstract] [Full Text] [Related]

  • 10. Alemtuzumab in chronic lymphocytic leukemia.
    James DF, Kipps TJ.
    Future Oncol; 2007 Feb 28; 3(1):29-42. PubMed ID: 17280499
    [Abstract] [Full Text] [Related]

  • 11. Effect of alemtuzumab on neoplastic B cells.
    Golay J, Manganini M, Rambaldi A, Introna M.
    Haematologica; 2004 Dec 28; 89(12):1476-83. PubMed ID: 15590398
    [Abstract] [Full Text] [Related]

  • 12. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ.
    Semin Oncol; 1999 Oct 28; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab (Millennium/ILEX).
    Dumont FJ.
    Curr Opin Investig Drugs; 2001 Jan 28; 2(1):139-60. PubMed ID: 11527007
    [Abstract] [Full Text] [Related]

  • 14. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S.
    Cancer; 2006 Jun 15; 106(12):2645-51. PubMed ID: 16688777
    [Abstract] [Full Text] [Related]

  • 15. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [Abstract] [Full Text] [Related]

  • 16. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P, Hillmen P.
    Semin Oncol; 2003 Aug 15; 30(4):493-501. PubMed ID: 12939718
    [Abstract] [Full Text] [Related]

  • 17. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.
    Clin Cancer Res; 2006 Dec 01; 12(23):7174-9. PubMed ID: 17145843
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab in T-cell malignancies.
    Dearden CE, Matutes E, Catovsky D.
    Med Oncol; 2002 Dec 01; 19 Suppl():S27-32. PubMed ID: 12180489
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab (Campath 1-H).
    Schaal AD.
    Clin J Oncol Nurs; 2005 Oct 01; 9(5):630-2. PubMed ID: 16235592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.